Cel-Sci Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$22.7MTTM through 30 Jun 2026
Free Cash Flow -$16.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-207.2%ROE
-106.3%ROA
Balance Sheet Health
Debt / Equity1.00x
Current Ratio1.48x
Net Debt-$843.4Knet cash position
Cash & Equivalents$6.5M
Quality Metrics
Altman Z-Score-38.03
Piotroski F-Score3 / 9
Multi-Year Trend
RevenueFY2014: $264K
Diluted EPS-$1.69TTMFY2025: $-6.27
Dividend
No dividend
Capital Allocation
R&D Spend$14.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Immunotherapy R&D | $0 | View detailsThe company is focused on initiating patient enrollment for its pivotal U.S. FDA confirmatory study by Summer/Fall 2026 and commercializing Multikine in Saudi Arabia via its strategic partnership with Amarox. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.